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Impact of Pharmacist-lead Antibiotic
Stewardship Program in a Pediatric Intensive
Care Unit (PICU)
Kashif Hussain, Specialist, Pharmacy Services

Antibiotic Stewardship Program (ASP) has improved the utilization of
antibiotics in hospitalized patients. We prospectively conducted a pilot project of
pharmacist-lead ASP, with audit and feedback, in a closed multidisciplinary PICU
and compared with historical control in utilization of antibiotics for 3 months.
The team of ASP is composed of Pharmacist who has expertise in ASP, pediatric
intensives and pediatric infectious disease consultants. Antibiotic exposure on
daily basis is considered as Day of Therapy (DOT). 135 and 127 patients were in
control and intervention group respectively. Patient’s characteristics were same
in both groups. DOT in control and intervention groups were 1937 & 1074 per
1000 patient days and 651 & 320 per1000 patient days respectively (p<0.001).
Similar reduction was noted in individual antibiotic except Colistin. Antibiotics
were stopped after 2 days in 8 patients in control group versus 57 patients in
intervention group. 29 (22.6%) pharmacist intervention were recorded; including
dose adjustment (11), selection of antibiotics (15), dose de-escalation (5) and
monitoring recommendation (6).
Duration alerts by pharmacist were not included in it. There was about >50%
cost saving in ASP period (PKR 2212468/= vs. 92568/=; p<0.001). There was
no difference in mortality between two groups. Pharmacist-lead ASP in a PICU
have a significant impact on decreasing use of antibiotics as well as cost-reducing
intervention.
References:
l

De Waele JJ, Schouten J, Dimopoulos G. Understanding antibiotic stewardship
for the critically ill. Intensive Care Med. 2016;42:2063-5.
Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ,
et al. Implementing an Antibiotic Stewardship Program: Guidelines by the
Infectious Diseases Society of America and the Society for Healthcare
Epidemiology of America. Clin Infect Dis. 2016; 62:e51-77.
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Levetiracetam is a second-generation, anti-epileptic drug, which is commonly
used as a mono- or adjunctive therapy for treating patients with partial and
generalized epilepsy. It is a highly soluble drug with high volume of distribution
(0.7L/kg) and half-life of 07 hours. The dosing regimen recommended is twice
daily. Due to its high volume of distribution, twice daily dosing regimen allows
steady state concentration to be achieved in two days. Furthermore, however,
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throughout the clinical trials evaluation program of Levetiracetam, a highly efficacious and sustainable effect was
observed with twice daily administration and indeed this is now the clinically practiced strategy.
Preferable Route of Administration: Oral product has 100 % bioavailability however, it may interact with food resulting
in reduction of 20% of maximum concentration and delay in time for peak by 1.5 hours. Cost effective value of oral is
much better than IV.
References:
l
l

Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinetic. 2004; 43(11):707-24.
Product Information: KEPPRA(R) oral tablets, solution, levetiracetam oral tablets, solution. UCB Inc., Smyrna, GA, 2008.

Management of Acute Hyperkalemia in Neonates
Gul Ambreen, Senior Pharmacist

Hyperkalemia is defined as a serum potassium concentration greater than 5.2 mmol/L (as far as neonate is
asymptomatic). Complications of hyperkalemia include ECG changes (peaked T waves, broad QRS complexes, and
arrhythmias), ventricular tachycardia and impaired AV conduction. Hyperkalemia in the NICU is most commonly
associated with non-oliguric hyperkalemia due to immature function of the erythrocyte Na/K – ATPase, Oliguric renal
failure and metabolic acidosis.
Treatment Strategies

Doses

10% Calcium Gluconate

•

0.5 ml/kg IV over 10-30 min. The dose of calcium gluconate may be repeated.

IV Dextrose and Insulin

•

Dextrose: 3-4 ml/kg/hr 25% dextrose in addition to maintenance fluid, aim for
blood glucose concentration (BGC) > 12 mmol/l. When BGC >12 mmol/L, start
insulin infusion (0.1-0.6 units/kg/hr).

Salbutamol

•

Nebulize: 400 micrograms/dose (made up to a total of 4 ml with normal saline)
up to 2 hrly.

Sodium bicarbonate
Correction of an existing metabolic
acidosis can be considered

•

Sodium bicarbonate dose (ml) = base deficit x 0.6 x weight (kg).

•

0.5 – 1 g/kg rectally

Polystyrene Sodium Sulfonate (should
be avoided in preterm infants)

Table 01: Treatment Strategies of Acute Hyperkalemia in Neonates
References:
l
Vemgal P, Ohlsson A. Interventions for non-oliguric hyperkalaemia in preterm neonates. Cochrane database Syst Rev.
		2012;5:CD005257.
l
Hu PS, Su BH, Peng CT, Tsai CH. Glucose and insulin infusion versus kayexalate for the early treatment of non-oliguric
		
hyperkalemia in very-low-birth-weight infants. Acta Paediatr Taiwan;40:314–8.
l
Singh BS, Sadiq HF, Noguchi A, Keenan WJ. Efficacy of albuterol inhalation in treatment of hyperkalemia in premature
		
neonates. J Pediatr. 2002 ;141:16–20.

Influenza Oral Tablet Vaccine Shows Promise in Phase 2 Trial
Hafsah M. Ashfaq- Clinical Pharmacist

A tablet vaccine for flu could significantly change the way we administer vaccines,”
An investigational H1 influenza oral tablet vaccine was found to provide comparable defense against influenza as an
injectable quadrivalent influenza vaccine (QIV) in a Phase 2 clinical trial.
The study results showed that the tablet vaccine has a good safety profile and it has provided a 39% reduction in clinical
disease relative to placebo, compared to a 27% reduction with injectable QIV.
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This oral vaccine is delivered to the epithelium of small intestine where they activate the local immune system of the
gut, and this in turn generates a broad local and systemic immune response. This vaccine does not enter the bloodstream
and prevents neutralization by blood or muscle tissue-based immune system. This effective way of administering
the vaccine in a tablet form will significantly increase the compliance and will provide health benefits for high risk
population.
Reference:
l
Influenza Oral Tablet Vaccine Shows Promise in Phase 2 Trial; http://www.empr.com/drug (Accessed 24/11/2017)

Drug Induced Neuroleptic Malignant Syndrome (NMS)
Mahreen Sohail, Trainee Pharmacist

The use of antipsychotic drugs can cause a rare, life-threatening, idiosyncratic condition known as Neuroleptic
malignant syndrome. NMS is characterized by hyperthermia, muscles rigidity, dysautonomia and mental status
changes. NMS mostly occur within 2 weeks of therapeutic initiation. Treatment involves immediate withdrawal of
causative agent and supportive care, which includes, volume resuscitation, correction of electrolyte abnormalities,
IV fluids and parenteral nutrition are recommended for patients in respiratory distress or those unable to tolerate oral
intake. Treatment includes, direct acting skeletal muscles relaxant, centrally acting dopamine agonist (bromocriptine
and amantadine) and benzodiazepines are reserved for patients who do not respond to withdrawal of medication and
supportive care.
Pharmacists play a crucial role in counseling the patient or the caregivers about the possible side effects and measures
taken in case of emergency, advising physicians on recognition of early symptoms and therapeutic options or
alternatives in NMS treatment.
Atypical
antipsychotics

Typical
antipsychotics
•
•
•
•
•
•
•

Chlorpromazine
Chlorprothixene
Haloperidol
Pimozide
Fluphenazine
Thioridazine
Trifluoperazine

•
•
•
•
•
•

Clozapine
Olanzapine
Quetiapine
Resperidone
Ziprasidone
Aripiprazole

Antiemetic
•
•
•
•

Dropiredol
Metoclopramide
Prochlorperazine
Promethazine

Dopaminergic
•
•
•
•
•

Amantidine
Bromocriptine
Carbidopa
Levodopa
Tolcapone

Others
•
•
•
•
•
•
•

Desipramine
Dosulpine
Lithium
Phenelzine
Reserpine
Tetrabenazine
Trimipramine

Table 02: List of Drug Associated with NMS
References:
l
Oruch R, Pryme IF, Engelsen BA, Lund A. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.
		
Neuropsychiatric disease and treatment. 2017; 13:161.
l
Buckley PF, Hutchinson M. Neuroleptic malignant syndrome. J Neurol Neurosurg Psychiatr. 1995; 58(3):271-273.

Drug-Drug Interaction – QT Interval Prolongation
Sumaira Khan, Specialist, Pharmacy Services

An elderly woman of 67 years old with history of stroke and diabetes mellitus (DM) was on multiple drugs including
Fluoxetine and Donepezil. Her heart monitoring showed prolonged QT waves. Pharmacist on clinical rounds identified
drug –drug interaction between Fluoxetine and Donepezil. Donepezil has been associated with QT-interval prolongation. Studies suggest to use caution when administering donepezil concomitantly with other drugs that cause QT-interval
prolongation like Fluoxetine as it may result in increased risk of QT-interval prolongation and torsade de pointes. Health
care team agreed with scientific evidence and discontinued the Fluoxetine.
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Reference:
l
Takaya T, Okamoto M, Yodoi K et al: Torsades de Pointes with QT prolongation related to donepezil use. J Cardiol Dec,
		2009; 54(3):507-511.
l
Tanaka A: Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade
		
de Pointes. Intern Med 2009; 48(14):1219-1223.

Influenza and Influenza Vaccine Myths and Reality
Drug & Poison Information Team
Acknowledge: This table has been accessed on 29th December, 2017, retrieved from
https://www.jointcommission.org/assets/1/6/JC_influenza_myths.pdf

Myth
•

Reality
•

The injectable flu vaccine does not contain the live virus so it is impossible to get influenza from the vaccine.
Side effects may occur in some people, such as mild soreness, redness, or swelling at the injection site, head
ache, or a low-grade fever. The nasal spray flu vaccine contains live, attenuated (weakened) viruses that can
cause mild signs or symptoms such as runny nose, fever, sore throat, and nasal congestion. This vaccine,
however, cannot cause influenza infection in the lower respiratory tract. Vaccination is safe and effective, and
the best way to help prevent influenza and its complications.

•

The influenza vaccine will prevent influenza most of the time. In scientific studies, the effectiveness of the
vaccine ranges from 70 to 90 percent, depending on how well the circulating viruses match those in the
vaccine. In populations in which the vaccine is less effective in preventing influenza, such as the elderly,
the vaccine reduces the severity of the disease and the incidence of complications by 50 to 60 percent and the
incidence of death by approximately 80 percent. Getting vaccinated is the most effective way to protect
against influenza and its serious outcomes.

The flu vaccine can cause
influenza.

•

The flu shot doesn’t
work.

•

•
Our staff follows
Standard Precautions,
with good hand hygiene
practices and appropriate
glove and mask use – so
vaccination is not necessary.

Influenza is spread by respiratory droplets generated when talking, coughing or sneezing. Adults shed
influenza virus at least one day before any signs or symptoms of the disease, so health care personnel can
unknowingly infect patients or other staff. 50 percent of influenza infections can be asymptomatic, and both
symptomatic and asymptomatic individuals can shed the virus and infect others.

•

Our staff stays at home if •
they are sick - so
vaccination is not
necessary.

Since unvaccinated individuals are contagious at least one day before any signs or symptoms of influenza
appear, they can still shed the virus and infect patients and other staff. Unvaccinated health care personnel
can become infected with influenza and not have any symptoms, and both symptomatic and asymptomatic
individuals can shed the virus and infect others.

•
•

There is no evidence to
support that influenza
vaccination of staff im
proves patient outcomes.

Health care personnel can acquire influenza from the community or their patients and can transmit it to
patients or other staff. Influenza transmission and outbreaks in health care organizations have been
recognized for many years and have been associated with substantial morbidity, mortality, and costs.
Influenza’s short incubation period and ease of transmission through respiratory droplets from person
to person can result in explosive outbreaks of febrile respiratory illness. Health care settings are favorable
environments for such transmission. Increased rates of staff vaccination result in decreased rates of
health care-associated influenza. In fact, one group of researchers concluded that the reduction in morbidity,
mortality, and use of health service resources associated with vaccinating their long term care facility was
“equivalent to preventing five deaths, two admissions to hospitals with influenza-like illness, seven general
practitioner consultations for influenza-like illness, and nine cases of influenza-like illness per 100 residents
during the period of influenza activity.”

•

•
Influenza vaccinations
for staff will be too costly.

The cost savings associated with health care personnel influenza vaccination programs generally outweigh
the costs associated with providing the vaccine, and vaccinating ultimately results in a safer environment for
patients.

Provide us your Valuable Feedback!

To keep the Pharmacy Newsletter of Aga Khan University Hospital (AKUH) updated we would like to take your valuable feedback. We are grateful
to you for sparing few minutes of your precious time to complete form by below online link or form can be emailed to you as well. Just drop us an
email with subject Newsletter Feedback. Email us at:drug.information@aku.edu
Thank you in advance for your feedback!
Link:
https://goo.gl/forms/Ghh1Nc2KY2jEkiUL2
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